Incruse ElliptaMarketed by: GlaxoSmithKlineIndication: The FDA has approved Incruse Ellipta (umeclidinium inhalation powder), an anticholinergic, for longterm, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse Ellipta is for oral inhalation only. The inhaler contains a double-foil blister strip of powder formulation. For maintenance treatment of COPD, 1 inhalation of Incruse Ellipta once daily is recommended.Dosage Form: Inhalation powder: umeclidinium 62.5 mcg per blisterFor More Information: www.gsk.comOtrexupMarketed by: Antares Pharma, IncIndication: The FDA has approved Otrexup (methotrexate) injection to treat rheumatoid arthritis (RA) and psoriasis in adults, and polyarticular idiopathic arthritis (pJIA) in children. Otrexup is for once-weekly subcutaneous use only and should be administered in the abdomen or thigh. The starting doses are as follows: for RA, 7.5 mg once weekly; for pJIA, 10 mg/ m2 once weekly; for psoriasis, 10 to 25 mg once weekly of an oral, intramuscular, subcutaneous, or intravenous formulation.Dosage Form: Single-dose autoinjector: 10, 15, 20, or 25 mgFor More Information: www.otrexup.comXartemis XRMarketed by: Mallinckrodt PharmaceuticalsIndication: The FDA has approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended- Release Tablets for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. The recommended dose of Xartemis XR is 2 tablets every 12 hours without regard to food. Tablets should be swallowed whole, and complete swallowing should be ensured immediately after placing them in the mouth.Dosage Form: Extended-release tablets (oxycodone hydrochloride/acetaminophen): 7.5 mg/325 mgFor More Information: www.xartemisxr.comRagwitekMarketed by: Merck & Co, IncIndication: The FDA has approved Ragwitek (short ragweed pollen allergen extract) as immunotherapy for the treatment of short ragweed pollenâ€“ induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age. The recommended dosage is 1 tablet daily sublingually.Dosage Form: Tablets: 12 Amb a 1-unitFor More Information: www.ragwitek.com
